Physician profile
David Thomas
NPI 1770515884
$4,562.66
in general payments reported to CMS, 2019-2025
26 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,755 · 2020: $581 · 2021: $950 · 2022: $560 · 2023: $374 · 2024: $131 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.01 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $922.57 | 2019-2025 | Rinvoq |
| Regeneron Healthcare Solutions, INC. | $593.08 | 2019-2021 | |
| Janssen Biotech, INC. | $387.62 | 2019-2025 | Tremfya |
| Pfizer INC. | $375.65 | 2019-2023 | |
| Leo Pharma INC. | $266.60 | 2019-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $242.74 | 2021-2022 | |
| Almirall LLC | $215.15 | 2019-2021 | |
| Epi Health, LLC | $207.20 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $197.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $147.57 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $146.95 | 2019-2025 | |
| Galderma Laboratories, L.P. | $133.13 | 2019-2024 | |
| Prugen, INC. Pharmaceuticals | $126.51 | 2019-2020 | |
| Lilly USA, LLC | $112.07 | 2020-2022 | |
| Stemline Therapeutics INC. | $86.05 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66.24 | 2021-2025 | Otezla |
| Incyte Corporation | $52.37 | 2022-2023 | Opzelura |
| Vyne Pharmaceuticals INC. | $47.86 | 2020 | |
| Sanofi-Aventis U.S. LLC | $44.14 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $34.90 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $33.37 | 2019 | |
| Dermavant Sciences, INC. | $31.77 | 2023 | Vtama |
| Celgene Corporation | $24.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.81 | 2022 | |
| Dermira, INC. | $23.20 | 2019 | |
| Journey Medical Corporation | $18.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.